 | • レポートコード：MRC2304L002 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、255ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：バイオ |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社は、2021年に2,461.84百万ドルであった世界のバイオシミュレーション市場規模が、2022年に2,874.69百万ドルへと拡大し、その後CAGR 16.94％で成長して2027年までに6,297.89百万ドルに達すると予測しています。当書は、バイオシミュレーションの世界市場を総合的に分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、製品＆サービス別（サービス、ソフトウェア）分析、配信モデル別（所有モデル、サブスクリプションモデル）分析、エンドユーザー別（受託研究機関、製薬＆バイオテクノロジー企業、規制当局、研究機関）分析、用途別（医薬品開発、創薬）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの項目をまとめています。なお、当書に掲載されている企業情報には、Advanced Chemistry Development、Certara、Chemical Computing Group ULC、Dassault Systèmes、Evidera、Gendata AG、In silico biosciences、INOSIM Software、Insilico Biotechnology AG、LeadInvent Pharma Incなどが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界のバイオシミュレーション市場規模：製品＆サービス別 - サービスの市場規模 - ソフトウェアの市場規模 ・世界のバイオシミュレーション市場規模：配信モデル別 - 所有モデルの市場規模 - サブスクリプションモデルの市場規模 ・世界のバイオシミュレーション市場規模：エンドユーザー別 - 受託研究機関における市場規模 - 製薬＆バイオテクノロジー企業における市場規模 - 規制当局における市場規模 - 研究機関における市場規模 ・世界のバイオシミュレーション市場規模：用途別 - 医薬品開発における市場規模 - 創薬における市場規模 ・世界のバイオシミュレーション市場規模：地域別 - 南北アメリカのバイオシミュレーション市場規模 アメリカのバイオシミュレーション市場規模 カナダのバイオシミュレーション市場規模 ブラジルのバイオシミュレーション市場規模 ... - アジア太平洋のバイオシミュレーション市場規模 日本のバイオシミュレーション市場規模 中国のバイオシミュレーション市場規模 インドのバイオシミュレーション市場規模 韓国のバイオシミュレーション市場規模 台湾のバイオシミュレーション市場規模 ... - ヨーロッパ/中東/アフリカのバイオシミュレーション市場規模 イギリスのバイオシミュレーション市場規模 ドイツのバイオシミュレーション市場規模 フランスのバイオシミュレーション市場規模 ロシアのバイオシミュレーション市場規模 ... - その他地域のバイオシミュレーション市場規模 ・競争状況 ・企業情報 |
The Global Biosimulation Market size was estimated at USD 2,461.84 million in 2021 and expected to reach USD 2,874.69 million in 2022, and is projected to grow at a CAGR 16.94% to reach USD 6,297.89 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Biosimulation to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Product & Service, the market was studied across Services and Software. The Services is further studied across Contract Services and In-house Services. The Software is further studied across Molecular Modeling and Simulation Software, Pbpk Modeling and Simulation Software, Pk/Pd Modeling and Simulation Software, Toxicity Prediction Software, and Trial Design Software.
Based on Delivery Model, the market was studied across Ownership Models and Subscription Models.
Based on End-user, the market was studied across Contract Research Organizations, Pharmaceutical And Biotechnology Companies, Regulatory Authorities, and Research Institutes.
Based on Application, the market was studied across Drug Development and Drug Discovery. The Drug Development is further studied across Clinical Trials and Preclinical Testing. The Preclinical Testing is further studied across Adme/Tox and Pk/Pd. The Drug Discovery is further studied across Lead Identification and Optimization and Target Identification and Validation.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Biosimulation market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Biosimulation Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Biosimulation Market, including Advanced Chemistry Development, Certara, Chemical Computing Group ULC, Dassault Systèmes, Evidera, Gendata AG, In silico biosciences, INOSIM Software, Insilico Biotechnology AG, LeadInvent Pharma Inc, Nuventra Pharma Sciences, Physiomics Plc, Rosa & Co. LLC., Schrödinger, Inc., and Simulations Plus.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Biosimulation Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Biosimulation Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Biosimulation Market?
4. What is the competitive strategic window for opportunities in the Global Biosimulation Market?
5. What are the technology trends and regulatory frameworks in the Global Biosimulation Market?
6. What is the market share of the leading vendors in the Global Biosimulation Market?
7. What modes and strategic moves are considered suitable for entering the Global Biosimulation Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Potential demand attributed to adaptations of biosimulation in various sectors such as biotechnology
5.1.1.2. Growing demand associated with application of biosimulation in clinical trials
5.1.1.3. Rising investments in drug developments and drug testings
5.1.2. Restraints
5.1.2.1. Upscaled prices involved in installations and technique developments for biosimulation
5.1.3. Opportunities
5.1.3.1. Favorable governmental laws and regulations to implement biosimulation
5.1.3.2. Increasing investments in research and development for utilization of biosimulation
5.1.4. Challenges
5.1.4.1. Lack of awareness coupled with scarcity of professionals for research and development
5.2. Cumulative Impact of COVID-19
6. Biosimulation Market, by Product & Service
6.1. Introduction
6.2. Services
6.3.1. Contract Services
6.3.2. In-house Services
6.3. Software
6.4.1. Molecular Modeling and Simulation Software
6.4.2. Pbpk Modeling and Simulation Software
6.4.3. Pk/Pd Modeling and Simulation Software
6.4.4. Toxicity Prediction Software
6.4.5. Trial Design Software
7. Biosimulation Market, by Delivery Model
7.1. Introduction
7.2. Ownership Models
7.3. Subscription Models
8. Biosimulation Market, by End-user
8.1. Introduction
8.2. Contract Research Organizations
8.3. Pharmaceutical And Biotechnology Companies
8.4. Regulatory Authorities
8.5. Research Institutes
9. Biosimulation Market, by Application
9.1. Introduction
9.2. Drug Development
9.3.1. Clinical Trials
9.3.2. Preclinical Testing
9.3.3.1. Adme/Tox
9.3.3.2. Pk/Pd
9.3. Drug Discovery
9.4.1. Lead Identification and Optimization
9.4.2. Target Identification and Validation
10. Americas Biosimulation Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Biosimulation Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Biosimulation Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. Advanced Chemistry Development
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. Certara
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Chemical Computing Group ULC
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Dassault Systèmes
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Evidera
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. Gendata AG
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. In silico biosciences
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. INOSIM Software
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Insilico Biotechnology AG
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. LeadInvent Pharma Inc
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Nuventra Pharma Sciences
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. Physiomics Plc
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. Rosa & Co. LLC.
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. Schrödinger, Inc.
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. Simulations Plus
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing